ClinicalTrials.gg
CompletedNCT04446260Updated Sep 15, 2025

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

A Phase 1 interventional study of SHR-A1811 in Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
396
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced/unresectable or solid tumor with expression or mutation that is to or intolerable with standard treatment, or for which no standard treatment is available
  • (ECOG) performance status of 0 or 1
  • ≥ 50% by either ECHO or MUGA
  • Has adequate renal and hepatic function
  • Female subjects agree not to be pregnant or lactating from beginning of the study screening until 6 months after receiving the last treatment

Exclusion criteria

Exclusion Criteria:

  • History of lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or suspected to have these diseases by imaging at screening period
  • Known hereditary or acquired bleeding and thrombotic tendency
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Part 1 Dose escalation

    Drug: SHR-A1811

  • Experimental
    Part 2 PK expansion

    Drug: SHR-A1811

  • Experimental
    Part 3 Indication expansion

    Drug: SHR-A1811

Interventions

  • be administered via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)

    Frequency and seriousness of treatment emergent adverse events (TEAEs)

    Time frame: From Day1 to 90 days after last dose

Secondary outcomes

  1. PK parameter: Tmax of SHR-A1811

    Time to maximal concentration (Tmax) of SHR-A1811

    Time frame: Through study completion, an average of 1 year

  2. PK parameter: Cmax of SHR-A1811

    Maximal concentration (Cmax) of SHR-A1811

    Time frame: Through study completion, an average of 1 year

  3. PK parameter: AUC0-t of SHR-A1811

    AUC computed from time zero to the time of the last quantifiable concentration (AUC0-t) of SHR-A1811

    Time frame: Through study completion, an average of 1 year

  4. Immunogenicity of SHR-A1811

    Including anti-drug antibody and/or neutralizing antibody

    Time frame: Through study completion, an average of 1 year

  5. Tumor response using RECIST 1.1

    RECIST=Response Evaluation Criteria in Solid Tumors Assessment of tumor response until disease progression or death to evaluate the efficacy of SHR-A1811 up to 30 months

    Time frame: From first dose to disease progression or death, whichever comes first, up to 30 months

07

Study locations

35 sites
  • Montefiore-Einstein Center for Cancer Care
    The Bronx, New York 10461, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • Macquarie University Hospital
    Macquarie, New South Wales 2109, Australia
  • Southern Oncology Clinical Research Unit
    Bedford Park, South Australia 5042, Australia
  • Peninsula and South Eastern Haematology & Oncology Group
    Frankston, Victoria 3199, Australia
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
  • Alfred Hospital
    Melbourne, 3004, Australia
  • The first affiliated hospital of bengbu medical college
    Bengbu, Anhui 233000, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
  • Fujian Cancer Hospital
    Fujian, Fuzhou 350000, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510120, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Henan cancer Hospital
    Zhengzhou, Henan 450003, China
  • Zhongnan hospital of Wuhan university
    Wuhan, Hubei 430062, China
  • Hubei cancer hospital
    Wuhan, Hubei 430079, China
  • Xiangya hospital central south university
    Changsha, Hunan 410008, China
  • Hunan cancer hospital
    Changsha, Hunan 410031, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210000, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Shengjing Hospital of China medical university
    Shengyang, Liaoning 110022, China
  • Fudan University Shanghai cancer center
    Shanghai, Shanghai Municipality 200032, China
  • Fudan Unversity Zhongshan Hospital
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai Jiao Tong University School of Medicine Renji Hospital
    Shanghai, Shanghai Municipality 200032, China
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030000, China
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610042, China
  • Tianjin medical university cancer institute&hoospital
    Tianjin, Tianjin Municipality 300181, China
  • The second affiliated hospital Zhejiang university school of medicine
    Hangzhou, Zhejiang 310014, China
  • Zhejiang provincial people's hospital
    Hangzhou, Zhejiang 310014, China
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Seoul National University Hospital
    Seoul, 3080, South Korea
  • Asan Medical Center
    Seoul, 5505, South Korea
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70457, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ, Kim JH, Zhong Y, Zhao Y, Voskoboynik M, Yin Y, Liu K, Kaubisch A, Liu C, Zhang J, Wang S, Im SA, Ganju V, Barve M, Li H, Ye C, Roy AC, Bai LY, Yen CJ, Gu S, Lin YC, Wu L, Bao L, Zhao K, Shen Y, Rong S, Zhu X, Song E. Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. J Clin Oncol. 2024 Oct 10;42(29):3453-3465. doi: 10.1200/JCO.23.02044. Epub 2024 Jun 20. PubMed 38900984 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jun 2025, 56 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jun 24, 2020
StartActual
Sep 7, 2020
Primary completionActual
Jun 4, 2025
CompletionActual
Jun 4, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04446260
Collaborators
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Sep 7, 2020
Primary completion
Jun 4, 2025
Completion
Jun 4, 2025
Last update
Sep 15, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion